Brainstorm Cell Therapeutics Inc. (BCLI)
R&D Expense Growth
-5.35%
Fiscal year · Period ending:
BCLI R&D Expense Growth
Latest reported-5.35%period ending
Latest reported-5.35%period ending
BCLI FY R&D Growth (YoY) (0.00% → -5.35%)
Latest values, visible window
High-resolution chart · PNG
BCLI r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -5.3503% | |
| -57.9143% | |
| -24.8997% | |
| -8.3951% | |
| -31.7703% | |
| 29.7896% | |
| 107.4521% | |
| 748.8229% | |
| -56.5778% | |
| -54.5363% | |
| 3.7091% | |
| 63.5927% | |
| 64.8023% | |
| 4.7957% | |
| 61.6268% | |
| 477.3481% | |
| -88.9567% | |
| -14.8571% | |
| 159.4609% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |